{
    "data": [
        {
            "id": "1912271",
            "type": "article",
            "attributes": {
                "publishOn": "2013-12-23T06:19:36-05:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "R117H Trial Puts Vertex In Scoring Position",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "54142",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "126639",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1912271-r117h-trial-puts-vertex-in-scoring-position"
            }
        },
        {
            "id": "1871881",
            "type": "article",
            "attributes": {
                "publishOn": "2013-12-02T13:49:47-05:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex: CF Drug Approval To Save The Company",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56822",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "125574",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1871881-vertex-cf-drug-approval-to-save-the-company"
            }
        },
        {
            "id": "1838722",
            "type": "article",
            "attributes": {
                "publishOn": "2013-11-14T05:52:16-05:00",
                "isLockedPro": false,
                "commentCount": 40,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex: A Biotech Value Investment",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "54142",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "124725",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/1838722-vertex-a-biotech-value-investment"
            }
        },
        {
            "id": "1821492",
            "type": "article",
            "attributes": {
                "publishOn": "2013-11-08T03:44:23-05:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Chasing Bubbles In The NASDAQ 100 (Part II)",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "30441",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1821492-chasing-bubbles-in-the-nasdaq-100-part-ii"
            }
        },
        {
            "id": "1765932",
            "type": "article",
            "attributes": {
                "publishOn": "2013-10-23T17:46:59-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Is Vertex A Decent Long-Term Buy For Growth Investors?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "54532",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "123660",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1765932-is-vertex-a-decent-long-term-buy-for-growth-investors"
            }
        },
        {
            "id": "1698332",
            "type": "article",
            "attributes": {
                "publishOn": "2013-09-17T09:41:28-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Can These Healthcare Stocks Be Winners?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "44981",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "121955",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1698332-can-these-healthcare-stocks-be-winners"
            }
        },
        {
            "id": "1688412",
            "type": "article",
            "attributes": {
                "publishOn": "2013-09-11T15:59:47-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex Pharmaceuticals: Dog Of The Nasdaq 100 Biotechs",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24757",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1688412-vertex-pharmaceuticals-dog-of-the-nasdaq-100-biotechs"
            }
        },
        {
            "id": "1579382",
            "type": "article",
            "attributes": {
                "publishOn": "2013-07-29T06:01:42-04:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex: Risk-Reward Less Favorable If HCV Pipeline Is In Question",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "52482",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "119371",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/1579382-vertex-risk-reward-less-favorable-if-hcv-pipeline-is-in-question"
            }
        },
        {
            "id": "1428321",
            "type": "article",
            "attributes": {
                "publishOn": "2013-05-13T02:31:00-04:00",
                "isLockedPro": false,
                "commentCount": 12,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "This Stock Deserved Its Sudden Upswing",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "48841",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "115806",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1428321-this-stock-deserved-its-sudden-upswing"
            }
        },
        {
            "id": "1417621",
            "type": "article",
            "attributes": {
                "publishOn": "2013-05-09T03:25:55-04:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex Debt Conversion Is Not Bad For Shareholders",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "48841",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "115662",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1417621-vertex-debt-conversion-is-not-bad-for-shareholders"
            }
        },
        {
            "id": "1398351",
            "type": "article",
            "attributes": {
                "publishOn": "2013-05-03T07:54:36-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex Pharmaceuticals Beats Analyst Expectations, Yet Insiders Continue To Sell More Shares",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "29111",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "223531",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1398351-vertex-pharmaceuticals-beats-analyst-expectations-yet-insiders-continue-to-sell-more-shares"
            }
        },
        {
            "id": "1364591",
            "type": "article",
            "attributes": {
                "publishOn": "2013-04-24T01:50:25-04:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex Spikes On Phase II Data, Then The CFO Sells His Shares",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "29111",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "223462",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1364591-vertex-spikes-on-phase-ii-data-then-the-cfo-sells-his-shares"
            }
        },
        {
            "id": "1355861",
            "type": "article",
            "attributes": {
                "publishOn": "2013-04-20T09:33:25-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Biotech Stocks Get A Turbo Boost From Vertex",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23870",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1355861-biotech-stocks-get-a-turbo-boost-from-vertex"
            }
        },
        {
            "id": "1273771",
            "type": "article",
            "attributes": {
                "publishOn": "2013-03-14T11:34:37-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex: The Sun Sets On Incivek, Rises On Its CF Franchise",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "35761",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "113101",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1273771-vertex-the-sun-sets-on-incivek-rises-on-its-cf-franchise"
            }
        },
        {
            "id": "1146191",
            "type": "article",
            "attributes": {
                "publishOn": "2013-01-31T08:22:58-05:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex's True Value Overlooked",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "38211",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "111170",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1146191-vertexs-true-value-overlooked"
            }
        },
        {
            "id": "1123061",
            "type": "article",
            "attributes": {
                "publishOn": "2013-01-21T11:21:36-05:00",
                "isLockedPro": false,
                "commentCount": 16,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why You Should Sell Vertex",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31851",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1123061-why-you-should-sell-vertex"
            }
        }
    ]
}